{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:53Z","timestamp":1787014133988,"version":"build-2736575974"},"reference-count":36,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>There is limited data on the incidence, prevalence, and treatments for myelofibrosis (MF) in Germany. This retrospective study examined claims data from 3.3 million insured individuals, spanning from 2010 to 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four sensitivity scenarios were explored to identify cases of MF. Point prevalence and cumulative incidence of MF were determined as of December 31, 2021, and within 2021, respectively. A cross\u2010sectional analysis used the main scenario definition of MF to identify cases and evaluate the period prevalence of patients receiving treatment for symptoms and\/or splenomegaly, including first\u2010line (1L) Janus kinase inhibitor (JAKi), second\u2010line, or further (2L+) MF\u2010related treatment therapies during 2021. The prevalence of anemia treatment was also reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The estimated standardized point prevalence of MF on December 31, 2021, was 9.9\u201312.4 cases per 100\u2009000 persons, and cumulative incidence in 2021 was 1.2\u20131.8 cases per 100\u2009000 persons. Standardized period prevalence in 2021 for MF patients receiving 1L JAKi and\/or 2L+ MF\u2010related treatment was 4.0 cases per 100\u2009000. Among these patients, 47.1%\u201353.7% required treatment for anemia, resulting in a period prevalence of 1.9\u20132.2 cases per 100\u2009000 individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The data reveal gaps in MF treatments and the need to improve patient quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.14284","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T08:06:52Z","timestamp":1722845212000},"page":"704-715","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myelofibrosis and anemia: A German claims data analysis to describe epidemiology and current treatment"],"prefix":"10.1111","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6996-9709","authenticated-orcid":false,"given":"Alexander","family":"Slowley","sequence":"first","affiliation":[{"name":"GSK, Value, Evidence and Outcomes Europe  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Weinmann","sequence":"additional","affiliation":[{"name":"GSK  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"d'Estrube","sequence":"additional","affiliation":[{"name":"GSK, Value, Evidence and Outcomes Europe  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelesitse","family":"Phiri","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian M.","family":"Karl","sequence":"additional","affiliation":[{"name":"GSK  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Glei\u00dfner","sequence":"additional","affiliation":[{"name":"GSK  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Mueller","sequence":"additional","affiliation":[{"name":"IPAM  Wismar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Junker","sequence":"additional","affiliation":[{"name":"Ingress\u2010Health HWM GmbH, a Cytel Company  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim R.","family":"G\u00f6thert","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ) University Hospital Essen  Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26050"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.07.019"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.319"},{"key":"e_1_2_11_6_1","unstructured":"European Medicines Agency.Fedratinib summary of product characteristics.2023https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inrebic-epar-product-information_en.pdf"},{"key":"e_1_2_11_7_1","unstructured":"Grie\u00dfhammerMBG D\u00f6hnerK GisslingerH et al.Primary myelofibrosis (PMF). Onkopedia Leitlinie.2021."},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283106"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100716"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000001"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01157-4"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12256"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.813500"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2016.31.10.1579"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12788"},{"key":"e_1_2_11_19_1","unstructured":"Hematological Malignancy Research Network.Prevalence of haematological malignancies in the UK 2019.2019https:\/\/hmrn.org\/statistics\/prevalence"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-019-00660-1"},{"issue":"4","key":"e_1_2_11_21_1","first-page":"281","article-title":"Epidemiology of myeloproliferative neoplasms and myelodysplastic syndrome in Germany 2017 to 2019","volume":"29","author":"Neuser P","year":"2023","journal-title":"Epidemiologie"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.245"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab058"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692988"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1741381"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.06.017"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1016933"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124651"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1749607"},{"key":"e_1_2_11_30_1","unstructured":"IQWiG.Dossierbewertung: Fedratinib (Myelofibrose). Bewertung gem\u00e4\u00df. 35a Abs. 1 Satz 11 SGB V.2021."},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"issue":"1","key":"e_1_2_11_32_1","first-page":"e145","article-title":"A consensus German Reporting Standard for Secondary Data Analyses, Version 2 (STROSA\u2010STandardisierte BerichtsROutine fur SekundardatenAnalysen)","volume":"78","author":"Swart E","year":"2016","journal-title":"Gesundheitswesen"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.3019"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000321525"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21594"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34103"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104575"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.14284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T04:16:47Z","timestamp":1739765807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.14284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/ejh.14284"],"URL":"https:\/\/doi.org\/10.1111\/ejh.14284","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"2024-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}